Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Elamipretide - Stealth BioTherapeutics

Next Previous
Drug Profile

Elamipretide - Stealth BioTherapeutics

Alternative Names: Bendavia; ELA-4; Elamipretide-hydrochloride - Stealth Biotherapeutics; Forzinity; MTP 131; Ocuvia; SBT-31; SPI-31; SS-31

Latest Information Update: 23 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cornell University; Institut de recherches cliniques de Montreal
  • Developer Stealth BioTherapeutics
  • Class Amides; Amines; Antihyperglycaemics; Eye disorder therapies; Guanidines; Heart failure therapies; Oligopeptides; Peptides; Phenols; Small molecules; Xylenes
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mitochondrial myopathies; Duchenne muscular dystrophy; Friedreich's ataxia; Leber's hereditary optic atrophy; Barth syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Barth syndrome
  • Phase III Dry age-related macular degeneration; Mitochondrial myopathies
  • Discontinued Acute kidney injury; Chronic heart failure; Corneal disorders; Diabetes mellitus; Diabetic macular oedema; Duchenne muscular dystrophy; Friedreich's ataxia; Heart failure; Leber's hereditary optic atrophy; Mitochondrial disorders; Neurodegenerative disorders; Reperfusion injury

Most Recent Events

  • 23 Sep 2025 Discontinued - Preclinical for Neurodegenerative disorders in USA (IV), before September 2025 (Stealth BioTherapeutics pipeline, September 2025)
  • 22 Sep 2025 Chemical structure information updated.
  • 22 Sep 2025 Discontinued - Phase-I for Chronic heart failure (In volunteers) in USA (PO), before September 2025 (Stealth BioTherapeutics pipeline, September 2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top